Strategic Initiative

Slingshot members are tracking this corporate initiative:

Inflazome announces acquisition by Roche (RHHBY)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY

100%

Additional Information

Management Comment
 Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need. Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.” Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
https://www.inflazom...
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Sep 21, 2020
Projected Implementation:
Q3, 2020
Relevance Tracked Until:
Q4, 2020
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Nlrp3 Inflammasome Inhibitors, Inflammatory Diseases